Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080197
Status:
COMPLETED
Last Update Posted:
2006-10-11
First Post:
2004-03-24
Brief Title:
Study to Evaluate the Efficacy Safety and Tolerability of E7070 in Metastatic Breast Cancer Patients
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline a Taxane and Capecitabine
Status:
COMPLETED
Status Verified Date:
2006-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if E7070 is an efficacious safe and tolerable treatment for patients with metastatic breast cancer who have failed or could not tolerate prior treatments with an anthracycline a taxane and capecitabine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None